Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The United States Patent and Trademark Office (USPTO) has issued new patent 7,875,592 to Progen Pharmaceuticals, which will be expired on 4 March 2025.
Subscribe to our email newsletter
The patent entitiled ‘Sulfated Oligosaccharide Derivatives’ protects Progen’s PG500 series of small molecule compounds and their use in a variety of therapeutic areas predominantly related to oncology.
Progen Pharma Research and Development director Ian Bytheway said protection of the intellectual property by this patent strengthens and extends their drug development portfolio for the PG500 series technology.
Progen Pharma CEO Sue MacLeman said it is pleasing to announce the granting of this patent in such a commercially important region and it represents an important milestone in the development and commercialisation of PG500 series technology, from which their lead compound PG545 has already commenced human clinical trials.